ENANTA PHARMACEUTICALS INC — Director's Dealing 2021

Nov 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENANTA PHARMACEUTICALS INC (ENTA)
CIK: 0001177648
Period of Report: 2021-11-01

Reporting Person: Adda Nathalie (Sr. VP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Common Stock	M	9547	$48.52	Acquired	36491	Direct
2021-11-01	Common Stock	S	1952	$84.31	Disposed	34539	Direct
2021-11-01	Common Stock	S	7495	$85.02	Disposed	27044	Direct
2021-11-01	Common Stock	S	100	$86.21	Disposed	26944.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Stock Option (Right to Buy)	$48.52	M	9547	Disposed	2027-11-17	Common Stock (9547)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.74 to $84.73, inclusive.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.74 to $85.63, inclusive.

F4: The option, representing a right to purchase a total of 23,500 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017).